A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients.
about
P2860
A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase III, randomized, non-i ...... nia in breast cancer patients.
@en
A phase III, randomized, non-i ...... nia in breast cancer patients.
@nl
type
label
A phase III, randomized, non-i ...... nia in breast cancer patients.
@en
A phase III, randomized, non-i ...... nia in breast cancer patients.
@nl
prefLabel
A phase III, randomized, non-i ...... nia in breast cancer patients.
@en
A phase III, randomized, non-i ...... nia in breast cancer patients.
@nl
P2093
P2860
P356
P1433
P1476
A phase III, randomized, non-i ...... nia in breast cancer patients.
@en
P2093
André Mattar
José Luiz Pedrini
João Nunes de Matos-Neto
Renato Peixoto Cramer-Junior
Roberto Hegg
Roberto Odebrecht Rocha
Sabina Bandeira Aleixo
Sylvie van-Eyll-Rocha
P2860
P304
P356
10.6061/CLINICS/2016(10)06
P577
2016-10-01T00:00:00Z